Vero and Atria will test whether tirzepatide changes a blood-based measure of brain age

Researchers discussed what organ-specific aging clocks might reveal about disease risk and what it would take to use them in patient care.

Author
HDM Staff
Save
Share
Helen Messier speaks with Osama Alsaleh on the Revv Stage.
Helen Messier and Osama Alsaleh. Photo credit: HLTH USA 2026.

    LAS VEGAS — Vero Bioscience and the Atria Research and Global Health Institute plan to compare a blood-based measure of brain age in people taking tirzepatide with that of people receiving usual care, Vero clinical advisor Dr. Helen Messier said Monday at HLTH USA. The study asks whether the drug changes a pattern of circulating proteins associated with brain aging, and whether that change tracks with other measures of brain health.

    Messier described the comparison during the organ-age panel moderated by Osama Alsaleh, head of partnerships at Plug and Play Health. Ryan Smith, founder and director of research at TruDiagnostic, joined her. The two guests brought different molecular data to the discussion: Vero uses proteins circulating in the blood, while TruDiagnostic analyzes patterns of DNA methylation, chemical marks on DNA.

    What would a change in brain age establish?

    Atria’s study description says researchers will follow participants treated with tirzepatide over six months and compare the proteomic readout with established biomarkers of brain health. Messier called for “prospective outcome studies” that could determine whether changes in scores correspond to outcomes such as fewer cases of Alzheimer’s disease. That would require evidence beyond what a six-month biomarker comparison can provide.

    Smith said TruDiagnostic contributed to an Eli Lilly analysis that found changes in several DNA-based aging measures after tirzepatide treatment. The conference report from the Aging Research and Drug Discovery meeting describes an analysis of about 100 participants in the tirzepatide arm of a 72-week trial involving people with overweight or obesity who did not have diabetes. Smith said the field needs “markers which are predictive of outcomes” to evaluate possible interventions without waiting decades for results. For tirzepatide, he said the next step is to show whether participants whose clock scores fell also faced less disease risk years later.

    When a score could change a clinical decision

    Alsaleh asked what should happen when a patient learns that their estimated heart age is higher than the rest of their organ scores. Messier said she would consider family history and look for corroboration in established cardiovascular measures before deciding what to do. Smith posed a related question about earlier whole-body scores: if two very different estimates lead to identical advice, “why test it at all?”

    In a Nature Medicine study, researchers used circulating proteins to estimate the age of 11 organs or systems in 44,498 UK Biobank participants and examined which scores were associated with later disease. Especially elevated brain-age estimates were associated with a higher rate of subsequent Alzheimer’s diagnoses. The study followed people over time and found associations. Whether using scores to select care improves patient outcomes remains an open question.

    Messier said “younger is not always better” when interpreting scores from different organs. She noted that the links between lower age estimates and mortality varied by organ. The same study found that younger brain and immune-system estimates were especially associated with lower mortality. How a score relates to a specific outcome matters more for clinical interpretation than treating every estimate as a target to lower.

    Evidence that could support adoption

    Smith pointed to ARPA-H’s PROSPR program, which aims to identify biological and physiological markers and develop ways to assess age-related health. He said reimbursement is a difficult prospect for tests that return a risk score, especially when people change employers and health plans before the benefits of preventive care can be measured.

    That leaves two questions for health systems and payers. One is whether an organ-age test adds enough information to change a decision that standard assessment would have missed. The other is whether acting on that information improves the outcomes patients care about. The planned Vero–Atria comparison can help researchers decide whether its brain-age measure merits that longer test.

    Osama Alsaleh, Helen Messier and Ryan Smith in conversation on the Revv Stage at HLTH USA.
    From left, Osama Alsaleh, Helen Messier and Ryan Smith discuss organ aging at HLTH USA. Photo by Health Data Management.